* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:52:19 ON 03 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.52	2.52

FILE 'REGISTRY' ENTERED AT 15:59:20 ON 03 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAY 2003 HIGHEST RN 509953-09-7
DICTIONARY FILE UPDATES: 2 MAY 2003 HIGHEST RN 509953-09-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10082521.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 CO2H,COOH,COSH,CHO,C(O)CH3

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss ful
SEARCH FAILED DUE TO A STRUCTURE QUERY ERROR
The structure query could not be searched.  Please review and revise
your structure query, especially checking the variable definitions and
attachments. In rare instances the failure may be due to a system
problem. Please contact your local STN Help Desk if you need
assistance.

=> s l1 full
FULL SEARCH INITIATED 16:00:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  57753 TO ITERATE

100.0% PROCESSED   57753 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.02

L2             0 SEA SSS FUL L1

=> s l1 sss
SAMPLE SEARCH INITIATED 16:00:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2986 TO ITERATE

 33.5% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        56444 TO    62996
PROJECTED ANSWERS:               0 TO        0

L3             0 SEA SSS SAM L1

=> s l1
SAMPLE SEARCH INITIATED 16:02:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2986 TO ITERATE

 33.5% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        56444 TO    62996
PROJECTED ANSWERS:               0 TO        0

L4             0 SEA SSS SAM L1

=> s l1 sss ful l1
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms.  L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles.  The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> s l1 sss ful
FULL SEARCH INITIATED 16:05:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  57753 TO ITERATE

100.0% PROCESSED   57753 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.02
```

```
L5             0 SEA SSS FUL L1

=> s l1
SAMPLE SEARCH INITIATED 16:05:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2986 TO ITERATE

 33.5% PROCESSED    1000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        56444 TO    62996
PROJECTED ANSWERS:               0 TO        0

L6             0 SEA SSS SAM L1

=> file caplus, uspatfull, biosis, medline, cancerlit, drugu
COST IN U.S. DOLLARS                          SINCE FILE     TOTAL
                                                ENTRY     SESSION
FULL ESTIMATED COST                            300.30      302.82

FILE 'CAPLUS' ENTERED AT 16:06:42 ON 03 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:06:42 ON 03 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:06:42 ON 03 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 16:06:42 ON 03 MAY 2003

FILE 'CANCERLIT' ENTERED AT 16:06:42 ON 03 MAY 2003

FILE 'DRUGU' ENTERED AT 16:06:42 ON 03 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=>

=> s isocoumarin#########
L7          1917 ISOCOUMARIN#########

=> s glucocorticoid####
L8        133145 GLUCOCORTICOID####

=> s dexamethason### or prednison###
L9        227511 DEXAMETHASON### OR PREDNISON###

=> s l7 and l8
L10           26 L7 AND L8

=> s l7 and l9
L11           17 L7 AND L9

=> s l10 or l11
L12           28 L10 OR L11

=> s l7 and cancer####
L13          143 L7 AND CANCER####

=> s l13 and l9
```

```
L14          17 L13 AND L9

=> s l13 and l8
L15          25 L13 AND L8

=> s l14 or l15
L16          27 L14 OR L15

=> s vincristin##
L17       86336 VINCRISTIN##

=> s doxorubicin##
L18      117909 DOXORUBICIN##

=> s cisplatin
L19      128154 CISPLATIN

=> s cyclophosphamid##
L20      156136 CYCLOPHOSPHAMID##

=> s l20 or l19 or l18 ro l17
MISSING OPERATOR L18 RO
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l20 or l19 or l18 or l17
L21      360550 L20 OR L19 OR L18 OR L17

=> s l21 and l7
L22          15 L21 AND L7

=> dup remove l16
PROCESSING COMPLETED FOR L16
L23          26 DUP REMOVE L16 (1 DUPLICATE REMOVED)

=> d l23 1-26 bib,ab

L23  ANSWER 1 OF 26  USPATFULL
AN      2003:112921  USPATFULL
TI      Method for the identification of active site protease inactivators
IN      Baig, Salman, Athens, GA, UNITED STATES
PA      The University of Georgia Research Foundation, Inc. (U.S. corporation)
PI      US 2003077653      A1   20030424
AI      US 2001-839428     A1   20010420 (9)
PRAI    US 2000-198685P     20000420 (60)
        US 2000-235123P     20000925 (60)
DT      Utility
FS      APPLICATION
LREP    MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN,
        55458
CLMN    Number of Claims: 26
ECL     Exemplary Claim: 1
DRWN    15 Drawing Page(s)
LN.CNT 5189
AB      A method for identifying active site inhibitors of a target protease.
        Kinetic assays are employed to identify peptide substrates that tightly
        bind to the active site of the target protease but are not easily
        cleaved. These noncleavalbe but tightly binding substrates are
        structurally modified to yield inhibitory compounds that, additionally,
        exhibit apparent specificity for a transition state or ground state
        configuration of the protease.

L23  ANSWER 2 OF 26  USPATFULL
AN      2003:37557  USPATFULL
```

TI Methods of screening compounds for bioactivity in organized tissue
IN Vandenburgh, Herman H., Providence, RI, UNITED STATES
Valentini, Robert F., Cranston, RI, UNITED STATES
PI US 2003027202 A1 20030206
AI US 2002-241618 A1 20020911 (10)
RLI Continuation of Ser. No. US 1999-252324, filed on 18 Feb 1999, ABANDONED
PRAI US 1998-75054P 19980218 (60)
US 1998-86370P 19980522 (60)
DT Utility
FS APPLICATION
LREP PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1414
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound.

L23 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:850322 CAPLUS
DN 137:333136
TI Tumor chemopotentiation using **isocoumarin** derivatives
IN Agata, Naoki; Kharbanda, Surender
PA USA
SO U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U. S. Ser. No. 794,417.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002165210	A1	20021107	US 2002-82521	20020223
US 2002019366	A1	20020214	US 2001-794417	20010227
PRAI US 2000-186071P	P	20000229		
US 2001-794417	A2	20010227		

AB A method for enhancing the efficacy of chemotherapy in the treatment of **cancer** in animals, particularly humans, is provided wherein **isocoumarin** derivs. that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy. NM-3 [2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid] showed antiangiogenic activity and enhanced **dexamethasone** -induced apoptosis in human multiple myeloma cells.

L23 ANSWER 4 OF 26 USPATFULL
AN 2002:198527 USPATFULL
TI METHODS OF SCREENING COMPOUNDS FOR BIOACTIVITY IN ORGANIZED TISSUE
IN VANDENBURGH, HERMAN H., PROVIDENCE, RI, UNITED STATES
VALENTINI, ROBERT F., CRANSTON, RI, UNITED STATES
PI US 2002106627 A1 20020808
AI US 1999-252324 A1 19990218 (9)
PRAI US 1998-75054P 19980218 (60)
US 1998-86370P 19980522 (60)
DT Utility
FS APPLICATION
LREP DAVID S. RESNICK, NIXON PEABODY, LLP, 101 FEDERAL STREET, BOSTON, MA, 02110-1832
CLMN Number of Claims: 17
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 1416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound.

L23 ANSWER 5 OF 26 USPATFULL
AN 2002:191193 USPATFULL
TI Peptide and polypeptide inhibitors of complement C1s
IN West, Robert R., Seattle, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Fox, Brian A., Seattle, WA, UNITED STATES
PI US 2002102256 A1 20020801
AI US 2001-883727 A1 20010618 (9)
PRAI US 2000-212998P 20000621 (60)
DT Utility
FS APPLICATION
LREP Phillip B.C. Jones, J.D., Ph.D., ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

L23 ANSWER 6 OF 26 USPATFULL
AN 2002:133832 USPATFULL
TI USE OF NF-KB INHIBITION IN COMBINATION THERAPY FOR CANCER
IN BALDWIN, ALBERT S., CHAPEL HILL, NC, UNITED STATES
CUSACK, JAMES C., CHAPEL HILL, NC, UNITED STATES
MAYO, MARTY W., DURHAM, NC, UNITED STATES
WANG, CUN-YU, CHAPEL HILL, NC, UNITED STATES
PI US 2002068690 A1 20020606
AI US 1997-959160 A1 19971028 (8)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, POST OFFICE BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of NF-.kappa.B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.

L23 ANSWER 7 OF 26 USPATFULL
AN 2002:32544 USPATFULL
TI Tumor radiosensitization and/or chemopotentiation using **isocoumarin** derivatives
IN Reimer, Corinne L., Sommersville, MA, UNITED STATES
Agata, Naoki, Fujisawa, JAPAN
Takeuchi, Tomio, Tokyo, JAPAN

Kumagai, Hiroyuki, Chigasaki City, JAPAN
Yoshioka, Takeo, Ayase-shi, JAPAN
Ishizuka, Masaaki, Mishima City, JAPAN
Kufe, Donald W., Wellesley, MA, UNITED STATES
Weichselbaum, Ralph R., Chicago, IL, UNITED STATES
PI US 2002019366 A1 20020214
AI US 2001-794417 A1 20010227 (9)
PRAI US 2000-186071P 20000229 (60)
DT Utility
FS APPLICATION
LREP Al A. Jecminek, Vice President, Licensing & Intellectual Property, Ilex Oncology Inc., 4545 Horizon Hill Blvd., San Antonio, TX, 78229
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of **cancer** in animals, particularly humans, is provided wherein certain **isocoumarin** derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy.

L23 ANSWER 8 OF 26 USPATFULL
AN 2002:231092 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Zhi, Lin, San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 6448405 B1 20020910
AI US 1997-947428 19971008 (8)
RLI Division of Ser. No. US 1995-465429, filed on 5 Jun 1995, now patented, Pat. No. US 5696127 Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Brobeck, Phleger & Harrison LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 10950
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 9 OF 26 USPATFULL
AN 2000:125236 USPATFULL
TI Intermediates for preparation of steroid receptor modulator compounds
IN Jones, Todd K., Solana Beach, CA, United States
Winn, David T., San Diego, CA, United States
Hamann, Lawrence G., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Farmer, Luc J., La Jolla, CA, United States

Davis, Robert L., Santee, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 6121450 20000919
AI US 1997-947427 19971008 (8)
RLI Division of Ser. No. US 1995-462643, filed on 5 Jun 1995, now patented, Pat. No. US 5696130 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Elmer, J. Scott, Respess, William L.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 10 OF 26 USPATFULL
AN 2000:95120 USPATFULL
TI Process for preparing steroid receptor modulator compounds
IN Jones, Todd K., Solana Beach, CA, United States
Goldman, Mark E., San Diego, CA, United States
Pooley, Charlotte L. F., San Diego, CA, United States
Winn, David T., San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 6093821 20000725
AI US 1997-943853 19971008 (8)
RLI Division of Ser. No. US 1995-464541, filed on 5 Jun 1995, now patented, Pat. No. US 5688810 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Elmer, J. Scott, Respess, William L.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 11 OF 26 USPATFULL
AN 1999:155927 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States

Tegley, Christopher M., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5994544 19991130
AI US 1997-947413 19971008 (8)
RLI Division of Ser. No. US 1995-464360, filed on 5 Jun 1995, now patented, Pat. No. US 5693646 which is a continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Elmer, J. Scott, Respess, William L.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10956
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors and the method of preparing these compounds are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 12 OF 26 USPATFULL
AN 1999:151182 USPATFULL
TI Agents affecting thrombosis and hemostasis
IN Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PA COR Therapeutics Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5990079 19991123
AI US 1998-16400 19980130 (9)
RLI Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1981
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L23 ANSWER 13 OF 26 USPATFULL
AN 1999:132526 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment

of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5972636 19991026
AI US 1997-982295 19971202 (8)
RLI Division of Ser. No. US 1996-730310, filed on 11 Oct 1996, now patented, Pat. No. US 5786329 which is a division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L23 ANSWER 14 OF 26 USPATFULL
AN 1999:128513 USPATFULL
TI Agents affecting thrombosis and hemostasis
IN Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5968897 19991019
AI US 1998-16403 19980130 (9)
RLI Continuation of Ser. No. US 1995-469301, filed on 6 Jun 1995, now patented, Pat. No. US 5837679 which is a division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy
LREP Morgan, Lewis & Bockius LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 24 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 1908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L23 ANSWER 15 OF 26 USPATFULL
AN 1998:144079 USPATFULL

TI Agents affecting thrombosis and hemostasis
IN Wolf, David L., Palo Alto, CA, United States
Sinha, Uma, San Francisco, CA, United States
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5837679 19981117
AI US 1995-469301 19950606 (8)
RLI Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5597799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144
DT Utility
FS Granted
EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Degen, Nancy J.
LREP Morrison & Foerster LLP
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 2092
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

L23 ANSWER 16 OF 26 USPATFULL
AN 1998:88814 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5786329 19980728
AI US 1996-730310 19961011 (8)
RLI Division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L23 ANSWER 17 OF 26 USPATFULL
AN 97:115291 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Goldman, Mark E., San Diego, CA, United States

Pooley, Charlotte L.F., San Diego, CA, United States
Winn, David T., San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Hamann, Lawrence G., San Diego, CA, United States
Farmer, Luc J., La Jolla, CA, United States
Davis, Robert L., Santee, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5696133 19971209
AI US 1995-465556 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 23 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiting steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 18 OF 26 USPATFULL
AN 97:115288 USPATFULL
TI Tricyclic steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Winn, David T., San Diego, CA, United States
Goldman, Mark E., San Diego, CA, United States
Hamann, Lawrence G., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Farmer, Luc J., La Jolla, CA, United States
Davis, Robert L., Santee, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5696130 19971209
AI US 1995-462643 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 19 OF 26 USPATFULL
AN 97:115285 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Zhi, Lin, San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5696127 19971209
AI US 1995-465429 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 20 OF 26 USPATFULL
AN 97:112477 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Zhi, Lin, San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Winn, David T., San Diego, CA, United States
Hamann, Lawrence G., San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5693647 19971202
AI US 1995-464546 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 21 OF 26 USPATFULL
AN 97:112476 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5693646 19971202
AI US 1995-464360 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 22 OF 26 USPATFULL
AN 97:107096 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Goldman, Mark E., San Diego, CA, United States
Pooley, Charlotte L.F., San Diego, CA, United States
Winn, David T., San Diego, CA, United States
Edwards, James P., San Diego, CA, United States
West, Sarah J., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5688810 19971118
AI US 1995-464541 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the

preparation of the steroid receptor modulator compounds.

L23 ANSWER 23 OF 26 USPATFULL
AN 97:107094 USPATFULL
TI Steroid receptor modulator compounds and methods
IN Jones, Todd K., Solana Beach, CA, United States
Winn, David T., San Diego, CA, United States
Zhi, Lin, San Diego, CA, United States
Hamann, Lawrence G., San Diego, CA, United States
Tegley, Christopher M., San Diego, CA, United States
Pooley, Charlotte L. F., San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 5688808 19971118
AI US 1995-463231 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-363529, filed on 22 Dec 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Huang, Evelyn
LREP Jurgensen, Thomas E., Respess, William L., Elmer, James Scott
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11240
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

L23 ANSWER 24 OF 26 USPATFULL
AN 97:3818 USPATFULL
TI Heterocyclic anthracycline analogs
IN Attardo, Giorgio, Laval, Canada
Kraus, Jean-Louis, Marseilles, France
Courchesne, Marc, Laval-des-Rapides, Canada
Lamonthe, Serge, Boisbriand, Canada
Lavall ee, Jean-Fran.cedilla.ois, Laval, Canada
Lebeau, Elaine, Kamloops, Canada
Nguyen, Dieu, Chomedey, Canada
Rej, Rabindra, Montreal, Canada
St-Denis, Yves, Montreal, Canada
Wang, Wuyi, St-Laurent, Canada
Xu, Yao-Chang, Indianapolis, IN, United States
Barbeau, France, Ste-Th er ese, Canada
Belleau, deceased, Bernard, late of Westmount, Canada by Pierette Belleau, executrix
PA Biochem Pharma Inc., Laval, Canada (non-U.S. corporation)
PI US 5593970 19970114
AI US 1994-263925 19940620 (8)
RLI Continuation-in-part of Ser. No. US 1993-2766, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-859244, filed on 26 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-536107, filed on 11 Jun 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Nixon & Vanderhye
CLMN Number of Claims: 34
ECL Exemplary Claim: 1,32

DRWN No Drawings
LN.CNT 10624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel pyrano heterocyclic anthracycline derivatives are described, which are useful in the treatment of **cancer** and tumors, such as breast **cancer**, leukemia, lung **cancer**, colon **cancer**, ovarian **cancer**, renal **cancer**, and melanoma. As well, these compounds may be used ex vivo for the treatment of **cancerous** bone marrow before retransplanting said marrow in a patient. Pharmaceutical compositions and methods of preparing the compounds are also described.

L23 ANSWER 25 OF 26 USPATFULL
AN 96:94482 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5565351 19961015
AI US 1994-262497 19940620 (8)
RLI Division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L23 ANSWER 26 OF 26 USPATFULL
AN 94:73223 USPATFULL
TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
IN Goldberg, Alfred L., Brookline, MA, United States
PA The President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5340736 19940823
AI US 1991-699184 19910513 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Sterne, Kessler, Goldstein & Fox
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2720
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced

proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

```
=> d his

     (FILE 'HOME' ENTERED AT 15:52:19 ON 03 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 15:59:20 ON 03 MAY 2003
L1             STRUCTURE UPLOADED
L2           0 S L1 FULL
L3           0 S L1 SSS
L4           0 S L1
L5           0 S L1 SSS FUL
L6           0 S L1

     FILE 'CAPLUS, USPATFULL, BIOSIS, MEDLINE, CANCERLIT, DRUGU' ENTERED AT
     16:06:42 ON 03 MAY 2003
L7        1917 S ISOCOUMARIN##########
L8      133145 S GLUCOCORTICOID####
L9      227511 S DEXAMETHASON### OR PREDNISON###
L10         26 S L7 AND L8
L11         17 S L7 AND L9
L12         28 S L10 OR L11
L13        143 S L7 AND CANCER####
L14         17 S L13 AND L9
L15         25 S L13 AND L8
L16         27 S L14 OR L15
L17      86336 S VINCRISTIN##
L18     117909 S DOXORUBICIN##
L19     128154 S CISPLATIN
L20     156136 S CYCLOPHOSPHAMID##
L21     360550 S L20 OR L19 OR L18 OR L17
L22         15 S L21 AND L7
L23         26 DUP REMOVE L16 (1 DUPLICATE REMOVED)

=> dup remove l22
PROCESSING COMPLETED FOR L22
L24         11 DUP REMOVE L22 (4 DUPLICATES REMOVED)

=> s l23 or l24
L25         34 L23 OR L24

=> d l24 1-11 bib,ab

L24  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2003 ACS        DUPLICATE 1
AN   2002:850322  CAPLUS
DN   137:333136
TI   Tumor chemopotentiation using isocoumarin derivatives
IN   Agata, Naoki; Kharbanda, Surender
PA   USA
SO   U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U. S. Ser. No. 794,417.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.         KIND  DATE          APPLICATION NO.   DATE
     ---------------    ----  --------      ----------------  --------
PI   US 2002165210      A1    20021107      US 2002-82521     20020223
     US 2002019366      A1    20020214      US 2001-794417    20010227
PRAI US 2000-186071P    P     20000229
     US 2001-794417     A2    20010227
AB   A method for enhancing the efficacy of chemotherapy in the treatment of
```

cancer in animals, particularly humans, is provided wherein **isocoumarin** derivs. that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy. NM-3 [2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid] showed antiangiogenic activity and enhanced dexamethasone-induced apoptosis in human multiple myeloma cells.

L24 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
AN 2002:123594 CAPLUS
DN 136:161349
TI Tumor radiosensitization and/or chemopotentiation using **isocoumarin** derivatives
IN Reimer, Corinne L.; Agata, Naoki; Takeuchi, Tomio; Kumagai, Hiroyuki; Yoshioka, Takeo; Ishizuka, Masaaki; Kufe, Donald W.; Weichselbaum, Ralph R.
PA USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002019366	A1	20020214	US 2001-794417	20010227
	WO 2002072143	A1	20020919	WO 2001-US7965	20010313
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002165210	A1	20021107	US 2002-82521	20020223
PRAI	US 2000-186071P	P	20000229		
	US 2001-794417	A	20010227		

OS MARPAT 136:161349
AB A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain **isocoumarin** derivs. which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy. Colon 26 adenocarcinoma cells transplanted in mice were inhibited with combination therapy of **cyclophosphamide** and 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid.

L24 ANSWER 3 OF 11 USPATFULL
AN 2002:133832 USPATFULL
TI USE OF NF-KB INHIBITION IN COMBINATION THERAPY FOR CANCER
IN BALDWIN, ALBERT S., CHAPEL HILL, NC, UNITED STATES
CUSACK, JAMES C., CHAPEL HILL, NC, UNITED STATES
MAYO, MARTY W., DURHAM, NC, UNITED STATES
WANG, CUN-YU, CHAPEL HILL, NC, UNITED STATES
PI US 2002068690 A1 20020606
AI US 1997-959160 A1 19971028 (8)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, POST OFFICE BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of NF-.kappa.B inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.

L24 ANSWER 4 OF 11 USPATFULL
AN 2002:239051 USPATFULL
TI **Isocoumarin** derivatives inhibiting angiogenesis
IN Lee, Jung Joon, Taejon-si, KOREA, REPUBLIC OF
Kim, Hang-Sub, Taejon-si, KOREA, REPUBLIC OF
Lee, Jeong-Hyung, Taejon-si, KOREA, REPUBLIC OF
Hong, Young-Soo, Taejon-si, KOREA, REPUBLIC OF
Park, Yun Joo, Taejon-si, KOREA, REPUBLIC OF
PA Korea Research Institute of Bioscience and Biotechnology, KOREA, REPUBLIC OF (non-U.S. corporation)
PI US 6451846 B1 20020917
WO 2000075124 20001214
AI US 2002-980904 20020226 (9)
WO 2000-KR576 20000601
20020226 PCT 371 date
PRAI KR 1999-20374 19990603
DT Utility
FS GRANTED
EXNAM Primary Examiner: Owens, Amelia
LREP Roberts & Mercanti, LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel **isocoumarin** derivatves inhibiting angiogenesis, a method for preparation thereof and pharmaceutical compositions comprising the said derivatives as pharmaceutically active ingredients. More particularly, the present invention relates to novel **isocoumarin** derivatves represented by formula (1), especially 6,8-dihydroxy-4-acetyl-**isocoumarin**, a method for preparing 6,8-dihydroxy-4-acetyl-**isocoumarin** from fungi, and pharmaceutical compositions comprising the compounds and/or 6,8-dihydroxy-4-acetyl-**isocoumarin** as pharmaceutically active ingredients, which would be effective for the treatment of angiogenic diseases such as cancers, rheumatoid arthritis and diabetic retinopathy.

L24 ANSWER 5 OF 11 USPATFULL
AN 2002:39931 USPATFULL
TI Camptothecin derivatives
IN Yang, Li-Xi, San Francisco, CA, United States
Pan, Xiandao, San Francisco, CA, United States
Wang, Huijuan, San Francisco, CA, United States
PA California Pacific Medical Center, San Francisco, CA, United States (U.S. corporation)
PI US 6350756 B1 20020226
AI US 2001-797769 20010301 (9)
PRAI US 2001-263040P 20010118 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Cooley Godward LLP
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an oxyalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the

camptothecin ring. The compounds are useful for treating cancer.

L24 ANSWER 6 OF 11 MEDLINE DUPLICATE 3
AN 2002099665 MEDLINE
DN 21818588 PubMed ID: 11830534
TI Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
AU Reimer Corinne L; Agata Naoki; Tammam Jennifer G; Bamberg Michael; Dickerson William M; Kamphaus George D; Rook Susan L; Milhollen Michael; Fram Robert; Kalluri Raghu; Kufe Donald; Kharbanda Surender
CS ILEX Oncology, Inc., 20 Overland Street, Boston, MA 02215, USA.
SO CANCER RESEARCH, (2002 Feb 1) 62 (3) 789-95.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200203
ED Entered STN: 20020207
Last Updated on STN: 20020307
Entered Medline: 20020305
AB Antiangiogenic therapy, although effective in shrinking tumors, has not yet been established as a standalone treatment for cancer. This therapeutic limitation can be overcome by combining angiogenesis inhibitors with chemotherapeutic agents. NM-3, a small molecule **isocoumarin**, is a recently discovered angiogenesis inhibitor. Here we demonstrate that NM-3 inhibits the proliferation of human umbilical vein endothelial cells in vitro, at concentrations 10-fold less than those required to inhibit normal fibroblasts or tumor cells (HT29, MKN28, and MCF-7). NM-3 alone inhibits endothelial sprouting and tube formation in vitro. The results also show that synergistic antiproliferative activity is observed when human umbilical vein endothelial cells are treated with NM-3 in combination with 5-fluorouracil. The effects of treatment with NM-3 and various chemotherapeutic agents were also evaluated in tumor xenografts. The results demonstrate that combined treatment with NM-3 and chemotherapeutic agents significantly reduced mean tumor volume compared with either treatment alone, with no effects on body weight changes. Taken together, these findings demonstrate that NM-3 is a well-tolerated angiogenesis inhibitor that significantly increases the efficacy of existing antineoplastic agents.

L24 ANSWER 7 OF 11 MEDLINE DUPLICATE 4
AN 2002193206 MEDLINE
DN 21923488 PubMed ID: 11926548
TI In vitro cytotoxicity of some natural and semi-synthetic **isocoumarins** from Paepalanthus bromelioides.
AU Devienne Karina F; Raddi MariaStellaG; Varanda Eliana A; Vilegas Wagner
CS Instituto de Quimica de Araraquara, SP, Brazil.
SO ZEITSCHRIFT FUR NATURFORSCHUNG. SECTION C. JOURNAL OF BIOSCIENCES, (2002 Jan-Feb) 57 (1-2) 85-8.
Journal code: 8912155. ISSN: 0341-0382.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200205
ED Entered STN: 20020404
Last Updated on STN: 20020511
Entered Medline: 20020510
AB Numerous natural compounds have a potential for therapeutic applications, but may have to be chemically modified to alter toxic side effects. We investigated structural parameters that could affect the cytotoxicity of **isocoumarins** similar to 9,10-dihydroxy-5,7-dimethoxy-1H-

naphtho(2,3c)pyran-1-one (paepalantine 1). Paepalantine 1 has antimicrobial activity, as well as significant in vitro cytotoxic effects in the McCoy cell line. Two other natural and two semi-synthetic **isocoumarins** with similar structures obtained from the capitula of Paepalanthus bromelioides were tested on the same cell line by the neutral red assay. Substitution of the 9 and/or 10-OH group made these compounds less cytotoxic.

L24 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS
AN 2000:351401 CAPLUS
DN 133:12742
TI A method of genetic vector delivery using immunosuppression and a blood-organ barrier modifier
IN Chiocca, E. Antonio; Ikeda, Keiro; Bartus, Raymond T.
PA The General Hospital Corporation, USA; Alkermes, Inc.
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000029033	A2	20000525	WO 1999-US27206	19991117
WO 2000029033	A3	20001005		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-108881P P 19981117
AB A method is provided for administering a genetic vector to a target cell in a patient by immunosuppressing the patient and administering the genetic vector. Also provided is a method of administering a genetic vector to a target cell in a patient by administering a complement inhibitor and the genetic vector. The invention also relates to further administering a blood-organ barrier modifier.

L24 ANSWER 9 OF 11 DRUGU COPYRIGHT 2003 THOMSON/DERWENT
AN 2001-04905 DRUGU P
TI NM3, an orally bioavailable small molecule inhibitor of VEGF expression inhibits xenograft tumor growth alone and enhances antitumor effects of standard chemotherapy.
AU Reimer C L; Rook C L; Dickerson M; Bamberg M; Rice G
CS Ilex-Oncology
LO Boston, Mass., USA
SO Clin.Cancer Res. (6, Suppl., 4520S, 2000)
CODEN: CCREF ISSN: 1078-0432
AV ILEX Oncology, Inc. Boston, MA 02215, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature
AB The antitumor activity of i.p. NM3, a small molecule **isocoumarin** that specifically inhibits VEGF expression at the mRNA and protein levels, alone and in combination with **cyclophosphamide** (CY), carboplatin (CB) and 5-fluorouracil (5-FU) was investigated in 2 different mouse xenograft tumor models. NM3 itself inhibited tumor growth and enhanced the responses to CY, CB and 5-FU. The findings support the use of NM3 in planned Phase I clinical trials alone and in combination with chemotherapy in patients with solid tumors. Its p.o.

bioavailability should confer greater dosing convenience than monoclonal antibody therapy and its 6-8 hr half-life should confer a greater safety profile than the prolonged half lives of anti-VEGF or anti-KDR antibodies. (conference abstract: 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 2000).

L24 ANSWER 10 OF 11 USPATFULL
AN 97:7935 USPATFULL
TI 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
IN Michalsky, deceased, Jiri, late of Olomouc, Czechoslovakia by Miluska Michalska, Jana Michalska, legal heirs
Hrbata, Jiri, Olsany, Czechoslovakia
Krepelka, Jiri, Praha, Czechoslovakia
Melka, Milan, Hradec Kralove, Czechoslovakia
Miko, Milan, Bratislava, Czechoslovakia
Hruby, Milan, Olomouc, Czechoslovakia
Ferenc, Milan, Olomouc, Czechoslovakia
Skacelova, Eva, Hnevotin, Czechoslovakia
Kejhova, Irena, Praha, Czechoslovakia
Reichlova, Rzena, Praha, Czechoslovakia
Kargerova, Anna, Praha, Czechoslovakia
Sediva, Jitka, Praha, Czechoslovakia
Kolonicny, Alois, Pardubice, Czechoslovakia
Urbanec, Josef, Hradec Kraalove, Czechoslovakia
PA VUFB a.s, Praha, Czechoslovakia (non-U.S. corporation)
PI US 5597831 19970128
AI US 1995-533859 19950926 (8)
RLI Continuation of Ser. No. US 1994-199153, filed on 13 Jul 1994, now abandoned
PRAI CS 1991-2669 19910829
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 11 OF 11 USPATFULL
AN 97:3818 USPATFULL
TI Heterocyclic anthracycline analogs
IN Attardo, Giorgio, Laval, Canada
Kraus, Jean-Louis, Marseilles, France
Courchesne, Marc, Laval-des-Rapides, Canada
Lamonthe, Serge, Boisbriand, Canada
Lavall ee, Jean-Fran.cedilla.ois, Laval, Canada
Lebeau, Elaine, Kamloops, Canada
Nguyen, Dieu, Chomedey, Canada
Rej, Rabindra, Montreal, Canada
St-Denis, Yves, Montreal, Canada
Wang, Wuyi, St-Laurent, Canada
Xu, Yao-Chang, Indianapolis, IN, United States
Barbeau, France, Ste-Th er ese, Canada
Belleau, deceased, Bernard, late of Westmount, Canada by Pierette Belleau, executrix
PA Biochem Pharma Inc., Laval, Canada (non-U.S. corporation)
PI US 5593970 19970114
AI US 1994-263925 19940620 (8)
RLI Continuation-in-part of Ser. No. US 1993-2766, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-859244, filed on 26 Mar 1992, now abandoned which is a continuation-in-part of

Ser. No. US 1990-536107, filed on 11 Jun 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Nixon & Vanderhye
CLMN Number of Claims: 34
ECL Exemplary Claim: 1,32
DRWN No Drawings
LN.CNT 10624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel pyrano heterocyclic anthracycline derivatives are described, which are useful in the treatment of cancer and tumors, such as breast cancer, leukemia, lung cancer, colon cancer, ovarian cancer, renal cancer, and melanoma. As well, these compounds may be used ex vivo for the treatment of cancerous bone marrow before retransplanting said marrow in a patient. Pharmaceutical compositions and methods of preparing the compounds are also described.